Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. [electronic resource]
Producer: 20131104Description: 989-98 p. digitalISSN:- 1474-5488
- Anastrozole
- Androstadienes -- adverse effects
- Antineoplastic Agents -- therapeutic use
- Aromatase Inhibitors -- administration & dosage
- Breast Neoplasms -- drug therapy
- Disease Progression
- Disease-Free Survival
- Estradiol -- administration & dosage
- Estrogen Antagonists -- administration & dosage
- Female
- Fulvestrant
- Humans
- Neoplasm Metastasis
- Nitriles -- administration & dosage
- Postmenopause
- Receptors, Estrogen -- analysis
- Triazoles -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.